Oral Wegovy (Semaglutide Tablets): Pharmacokinetics From the FDA Label

This is a reference page. Its job is to reproduce, accurately and with attribution, what the FDA-approved United States prescribing information states about the oral semaglutide tablet indicated for weight management, so somebody keeping a personal record can see where the numbers come from.

It is not medical advice. It has not been written or reviewed by a clinician, and it makes no recommendation about whether any medication or any strength is appropriate for anybody. It does not tell you how much to take, when, or how.

The oral products in this class are the ones most often described incorrectly online, usually by treating a tablet milligram figure as though it meant the same thing as an injection milligram figure. Correcting that is most of what this page is for.

Every figure on this page comes from one document: WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use — the United States Prescribing Information approved by the FDA, read on DailyMed accessed 1 September 2026. The label records an Initial U.S. Approval of 2017.

The structure of the current label is the thing to understand. One prescribing information document now covers two presentations of the same molecule: a subcutaneous injection and an oral tablet. Section 3, Dosage Forms and Strengths, enumerates both sets of strengths. Section 12.3, Pharmacokinetics, gives figures for both routes, and those figures are not the same.

This page is about the tablet. Where a figure differs by route, the tablet's figure is the one quoted, and it is identified as such.

This is the distinction most likely to be got wrong, so it is worth stating plainly.

There are two oral semaglutide products with separate labeling. The tablet covered by the Wegovy prescribing information carries an estimated absolute bioavailability of approximately 1% to 2%, and its labeled strengths are 1.5 mg, 4 mg, 9 mg and 25 mg. Rybelsus, indicated for type 2 diabetes, carries an estimated absolute bioavailability of approximately 0.4% to 1%, with strengths of 3 mg, 7 mg and 14 mg.

The ranges overlap at one percent but they are not the same range, and the strengths are entirely different. A figure quoted for one product should never be attributed to the other. Reference tables that collapse both into a single "oral semaglutide" row lose a real distinction that the approved labeling maintains.

A reader who knows the injection strengths and then meets a 25 mg tablet often assumes something dramatic is going on. It is not. It is arithmetic about absorption.

The injection's absolute bioavailability is 89%: the great majority of what is administered reaches the circulation. The tablet's is estimated at approximately 1% to 2%: a small fraction does. To deliver a broadly comparable quantity of drug into the body by a route that admits only a few percent of what is swallowed, the amount swallowed has to be much larger.

So the difference in the numbers on the two packages is a difference in what the numbers are measuring, not a difference in how much medication ends up in a person. This is why comparing tablet milligrams with injection milligrams is meaningless, and why bioavailability is the figure that makes any comparison possible at all.

Section 12.3 gives an elimination half-life of approximately 1 week for semaglutide, and states that the tablet's maximum concentration is reached 1 hour post dose.

Those two figures together describe a specific pattern. Each dose produces a fast rise, because absorption from the gut is quick. But clearance is slow, on the scale of a week. So each daily dose lands on top of a background that has barely diminished since the previous one, and levels climb across weeks before settling.

The practical consequence for record-keeping is the one that recurs throughout this pillar: an individual day is not an isolated event. What a person experiences in a given week reflects an accumulated level that many previous days contributed to, and a record that spans weeks is therefore far more informative than a note about a single day.

The tablet is escalated stepwise rather than started at a maintenance strength, and the prescribing information describes that escalation in its dosage and administration section.

This page does not reproduce it — not the steps, not the intervals, not the conditions for moving between strengths. The information is public and anybody can read the label, but a titration schedule is only meaningful attached to a specific person, and a page that publishes one is effectively handing readers a plan nobody qualified has given them.

The same applies to the administration conditions the label sets for oral semaglutide. That such conditions exist, and that they materially affect absorption, is a pharmacological fact worth knowing. The specific instructions are on your own prescription and belong to your pharmacist, not to a website.

GLP-1 Tracker records what you enter: which days you logged a dose, the strength as it was prescribed to you, weight and BMI entries over time, meals captured through the photo scan with calories, protein and fiber estimated, and notes about how a stretch of days went.

For a daily oral medication the useful pattern is adherence over time rather than individual events, and a continuous record is what makes that visible. It is also what makes a strength change legible afterwards — being able to see what the weeks either side actually looked like beats reconstructing them at an appointment.

What the app does not do is decide anything. It does not evaluate whether a routine is working, it does not flag anything as clinically significant, and it does not generate schedules.

GLP-1 Tracker includes an educational medication-level view that draws a curve from logged doses and a published half-life figure, corrected for how much of each dose is absorbed.

For an oral product that correction is drawn from a labeled range rather than measured, which means the curve rests on a modelled assumption sitting inside another modelled assumption. It is a teaching illustration — useful for seeing why a daily tablet accumulates over weeks — and it is nothing beyond that.

It cannot account for your own absorption, which is precisely the quantity the label declines to state as a single number. It is not a measurement, not a blood level, and not a clinical reading, and it should never influence anything you do.